Clinical Trials · NCT00075192
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 8
- Start date
- Mar 2004
- Locations
- 11 sites, United States
- Primary endpoint
- Assess safety of combination therapy and effectiveness as assessed by pathological response after 3 months of treatment follow for disease status for a maximum of 24 months